 The FDA approved the drug in 1997.Neumega is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.Efficacy was demonstrated in patients who had experienced severe thrombocytopenia following the previous chemotherapy cycle.